Aripiprazole and quetiapine in the treatment of patients with «dual diagnosis» of schizophrenia and drug addiction
Иванец Н. Н., Винникова М. А., Ежкова Е. В., Титков М. С., Булатова Р. А.
Журнал неврологии и психиатрии им. C.C. Корсакова
Т. 119, Вып. 9, С. 52-61
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.17116/jnevro201911909152
Аннотация:
Objective. The randomized comparative study of aripiprazole and quetiapine in the treatment of patients with “dual diagnosis” of schizophrenia and drug addiction. Material and methods. Intra-group analysis of dependent variables on the scales PANSS, BPRS, VAS, SACS showed significant differences in the dinamics of the therapy in all groups. A comparative randomized study included 90 men admitted to an inpatient addiction unit. Of these, 54 (60[%]) had a previously established psychiatric diagnosis and 36 patients (40[%]) did not have an established psychiatric diagnosis. They were randomized into 3 groups of 30 patients each: group 1 received aripiprazole at a dose of up to 20 mg/day, group 2 received quetiapine at a dose of up to 600 mg/day and group 3 (controls) was treated with haloperidol at a dose of up to 30 mg/day. Treatment duration was 21 days. The efficacy of aripiprazole and quetiapine was evaluated with PANSS, BPRS, VAS and SACS on 10th, 14th and 21st day (visits 2—4). Drug saf
Ключевые слова:
Aripiprazole; Atypical antipsychotics; Craving; Drug addiction; Dual diagnosis; Quetiapine; Schizophrenia
aripiprazole; haloperidol; quetiapine; dibenzothiazepine derivative; neuroleptic agent; Article; clinical feature; comparative study; controlled study; drug dependence; drug efficacy; drug safety; human; major clinical study; male; psychiatric diagnosis; schizophrenia; treatment duration; drug dependence; psychological rating scale; randomized controlled trial; schizophrenia; treatment outcome; Antipsychotic Agents; Aripiprazole; Diagnosis, Dual (Psychiatry); Dibenzothiazepines; Humans; Male; Psychiatric Status Rating Scales; Quetiapine Fumarate; Schizophrenia; Substance-Related Disorders; Treatment Outcome
Язык текста: Русский
ISSN: 2309-4729
Иванец Н. Н. Николай Николаевич 1941-
Винникова М. А. Мария Алексеевна 1971-
Ежкова Е. В.
Титков М. С.
Булатова Р. А.
Ivanets N. N. Nikolay Nikolaevich 1941-
Vinnikova M. A. Mariya Alekseevna 1971-
Ezhkova E. V.
Titkov M. S.
Bulatova R. A.
Aripiprazole and quetiapine in the treatment of patients with «dual diagnosis» of schizophrenia and drug addiction
Текст визуальный непосредственный
Журнал неврологии и психиатрии им. C.C. Корсакова
Издательство Медиа Сфера
Т. 119, Вып. 9 С. 52-61
2019
Статья
Aripiprazole Atypical antipsychotics Craving Drug addiction Dual diagnosis Quetiapine Schizophrenia
aripiprazole haloperidol quetiapine dibenzothiazepine derivative neuroleptic agent Article clinical feature comparative study controlled study drug dependence drug efficacy drug safety human major clinical study male psychiatric diagnosis schizophrenia treatment duration drug dependence psychological rating scale randomized controlled trial schizophrenia treatment outcome Antipsychotic Agents Aripiprazole Diagnosis, Dual (Psychiatry) Dibenzothiazepines Humans Male Psychiatric Status Rating Scales Quetiapine Fumarate Schizophrenia Substance-Related Disorders Treatment Outcome
Objective. The randomized comparative study of aripiprazole and quetiapine in the treatment of patients with “dual diagnosis” of schizophrenia and drug addiction. Material and methods. Intra-group analysis of dependent variables on the scales PANSS, BPRS, VAS, SACS showed significant differences in the dinamics of the therapy in all groups. A comparative randomized study included 90 men admitted to an inpatient addiction unit. Of these, 54 (60[%]) had a previously established psychiatric diagnosis and 36 patients (40[%]) did not have an established psychiatric diagnosis. They were randomized into 3 groups of 30 patients each: group 1 received aripiprazole at a dose of up to 20 mg/day, group 2 received quetiapine at a dose of up to 600 mg/day and group 3 (controls) was treated with haloperidol at a dose of up to 30 mg/day. Treatment duration was 21 days. The efficacy of aripiprazole and quetiapine was evaluated with PANSS, BPRS, VAS and SACS on 10th, 14th and 21st day (visits 2—4). Drug saf